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Background: The authors evaluate the efficacy and safety of ge-
fitinib monotherapy in chemotherapy-naive patients with advanced
non–small-cell lung cancer (NSCLC). A secondary endpoint is to
evaluate the relationship between clinical manifestations and epi-
dermal growth factor receptor (EGFR) mutation status.
Methods: Japanese chemotherapy-naive NSCLC patients were en-
rolled. They had measurable lesions, Eastern Cooperative Oncology
Group performance status of 0 to 2, and adequate organ and bone
marrow function. Patients received 250 mg of oral gefitinib daily.
EGFR mutations in exon 18, 19, and 21 of DNA extracted from
tumor and serum were analyzed by genomic polymerase chain
reaction and direct sequence.
Results: All 30 patients were eligible for the assessment of efficacy
and safety. An objective response and stable disease were observed
in 10 patients (33.3%) and nine patients (30.0%), respectively. The
median time to progression was 3.3 months and the median overall
survival was 10.6 months. The 1-year survival rate was 43.3%.
Grade 3 toxicities were observed in seven patients. EGFR mutation
was observed in four of 13 (30.8%) tumors, and two of them
achieved partial response. In serum samples, three of 10 patients
with EGFR mutations in the serum before treatment had a response
to gefitinib. EGFR mutation was observed in 10 of 27 and signifi-
cantly more frequently observed in the posttreatment samples from
patients with a partial response or stable disease than in those from
patients with progressive disease (p  0.006).
Conclusions: Gefitinib monotherapy in chemotherapy-naive
NSCLC patients was active, with acceptable toxicities. These results
warrant further evaluation of gefitinib monotherapy as a first-line
therapy. The EGFR mutation in serum DNA may be a biomarker for
monitoring the response to gefitinib during treatment.
Key Words: Non–small-cell lung cancer, Gefitinib, Epidermal
growth factor receptor, Mutation, Serum DNA.
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Non–small-cell lung cancer (NSCLC) is the leading causeof cancer death in Japan and throughout the world.1
Unfortunately, the majority of patients with NSCLC present
with locally advanced or metastatic disease at the time of
diagnosis. Although chemotherapy has produced modest sur-
vival benefits in advanced NSCLC patients, the outcome of
chemotherapy for NSCLC remains unsatisfactory.
Protein tyrosine kinases play important roles in the
pathogenesis of malignant tumors.2 Among them, epidermal
growth factor receptor (EGFR) tyrosine kinase has been
implicated in the initiation and progression of NSCLC.3–5
The overexpression of EGFR is frequent in NSCLC.6 Mono-
clonal antibodies and low-molecular-weight compounds that
inhibit the EGFR signaling pathway have been developed and
shown to have antitumor effects. Gefitinib (Iressa, Astra-
Zenca, London, England) is an orally active EGFR type
tyrosine kinase inhibitor. In four phase I studies, tumor
shrinkage or stabilization after gefitinib monotherapy was
observed in some patients with NSCLC. In two phase II trials,
Iressa Dose Evaluation in Advanced Lung cancer (IDEAL) 1
and 2, gefitinib monotherapy was shown to have a substantial
effect in NSCLC patients treated previously with chemother-
apy.7,8 In these trials, patients of Asian origin and who had
never been smokers had a statistically significant improve-
ment in overall survival. In spite of encouraging results in the
IDEAL trials, two large-scale, phase III, randomized trials,
Iressa NSCLC Trial Assessing Combination Treatment,
failed to show any survival benefit for the use of gefitinib.9,10
Patients in a large-scale phase III trial comparing gefitinib
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and placebo in advanced NSCLC with prior chemotherapy
demonstrated in preliminary analysis a tendency to have
improvement in overall survival but did not have a statisti-
cally significant improvement in overall survival.11 There are
many issues that need to be addressed with regard to the
clinical application of gefitinib; one of the most important
issues is the efficacy of gefitinib monotherapy in patients with
chemotherapy-naive NSCLC,12 and another is to establish a
way to predict response to gefitinib.
Recently, it has been suggested that mutations in the
EGFR tyrosine kinase domain play a critical role in deter-
mining tumor response to gefitinib in NSCLC patients.13,14
The mutations consisted of small, in-frame deletions or sub-
stitutions clustered around the adenosine triphosphate–bind-
ing site in exons 18, 19, and 21 of the EGFR. After these
reports, some investigators supported the belief that EGFR
mutation is one of the strong determinants of tumor response
to gefitinib.15–17 Tumors with EGFR mutations tend to be
more common in adenocarcinomas, female patients, non-
smokers, and those of Asian origin. In most of those studies,
tumor samples that were resected by operations were used.
Because it is often difficult to obtain a tumor sample from an
inoperable NSCLC patient, it is necessary to establish a
method for detecting mutant EGFR from a patient sample
other than from tumor specimens.
Polymerase chain reaction (PCR) technology for the
amplification of small amounts of DNA has made it possible
to identify the same alterations typically observed in DNA
from serum samples from NSCLC patients.18,19 Serum DNA
may provide a noninvasive and repeatable source of geno-
typic information that could influence treatment and progno-
sis, especially in advanced NSCLC patients who have re-
ceived gefitinib therapy. We essentially consider that it is
possible to detect the EGFR mutation in serum DNA. We
hypothesized that serum DNA may provide useful informa-
tion on EGFR mutations in lung cancer patients.
As described above, the usefulness of gefitinib mono-
therapy is controversial and that in patients without pretreat-
ment is unclear. Because EGFR mutations have been shown
to be strongly associated with the response of NSCLC pa-
tients to gefitinib treatment, the analysis of EGFR mutations
is necessary to evaluate the clinical benefit of gefitinib. We
therefore conducted a multicenter phase II trial for these
patients. The primary objective was to evaluate the objective
response rate, and secondary objectives were to estimate the
disease control rate, disease-related symptom improvement
rate, safety, time to progression (TTP), and overall survival
(OS). In addition, as a correlative study, we planned to detect
EGFR mutations in serum samples from NSCLC patients and
evaluate the relationship between the EGFR mutation and
clinical manifestations in NSCLC patients receiving gefitinib
treatment.
PATIENTS AND METHODS
Patient Eligibility
Patients who had histologically or cytologically proven
stage IIIb or IV NSCLC and no previous chemotherapy were
enrolled into this trial. Radiotherapy for metastatic lesions
until 3 weeks before entry was allowed on condition that
these lesions were not assessed for tumor response. Patients
in whom recurrence occurred after surgery were also eligible.
Patient eligibility criteria included at least one measurable
lesion, age of 20 years or older, Eastern Cooperative Oncol-
ogy Group performance status (PS) of 0 to 2, and life
expectancy of greater than or equal to12 weeks. Adequate
organ and bone marrow function was necessary, defined as
leukocyte counts greater than or equal to 3.0  106/liter,
neutrophil counts greater than or equal to 1.5  106/
liter, platelet counts greater than or equal to 100  109/liter,
hemoglobin levels greater than or equal to 8.5 g/dl, alanine
aminotransferase or aspartate aminotransferase levels less
than or equal to two times the upper limit of the reference
range (100 IU/liter in the presence of liver metastases),
serum bilirubin levels less than or equal to 1.5 mg/dl, serum
creatinine levels less than or equal to1.5 mg/dl, and PaO 2
levels greater than or equal to 65 mmHg. Patients with any of
the following were excluded: active double cancer; severe
complications such as myocardial infarction within 3 months
before entry or uncontrolled diabetes; symptomatic brain or
bone metastasis; diarrhea more severe than grade 2 according
to National Cancer Institute Common Toxicity Criteria ver-
sion 2; systemic administration of steroids to treat skin
diseases; pleural, pericardial, or peritoneal effusion requiring
treatment; and pregnancy or lactation. All patients were
required to give informed consent.
Treatment
Patients were treated with gefitinib 250 mg orally once
per day. Treatment was discontinued when the disease pro-
gressed, intolerable toxicities appeared, the patients requested
withdrawal, or disease-related symptoms worsened without
tumor response after 8 weeks of gefitinib monotherapy. These
patients received chemotherapeutic treatment after gefitinib
therapy. The chemotherapy regimen consisted of platinum
(cisplatin or carboplatin) plus new agents (paclitaxel, do-
cetaxel, gemcitabine, vinorelbine, or irinotecan) in patients
aged 74 years or younger and vinorelbine monotherapy in
patients aged 75 years or older. If symptomatic bone or brain
metastasis occurred during gefitinib monotherapy, patients
received radiotherapy after gefitinib treatment.
Efficacy and Drug-Related Adverse Events
Tumor size was assessed with computed tomography or
magnetic resonance imaging scans every 4 weeks from the
start to cessation of protocol treatment, using Response Eval-
uation Criteria in Solid Tumors guidelines.20 Disease control
was judged when patients achieved the best response of
complete response, partial response (PR), or stable disease
(SD), which was confirmed and sustained for 4 weeks. TTP
was measured as the period from the start of the treatment to
an identifiable time of disease progression. OS was measured
from the start of the treatment until death or the last follow-
up. The Kaplan-Meier method was used to calculate these
measures.
Drug adverse events were recorded and graded accord-
ing to National Cancer Institute Common Toxicity Criteria
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version 2.0. Changes in physical and laboratory findings were
assessed at least every 2 weeks.
Serum Sample Collection and DNA Extraction
Blood samples from patients were collected before and
14 days after the initiation of gefitinib administration. Sepa-
rated serum was stocked at –80°C until use. DNA extraction
from the serum samples was performed using a nonorganic
method (Oncor, Gaithersburg, MD). Serum DNA was puri-
fied using Qiamp Blood Kit (Qiagen, Hilden, Germany), with
the following protocol modifications. One column was used
repeatedly until the whole sample had been processed. The
extracted DNA was stocked at –20°C until use.
Tissue Sample Collection and DNA Extraction
Tumor specimens were obtained on protocols approved
by the institutional review board. Twenty paraffin blocks of
tumor material, obtained from 15 patients for diagnosis be-
fore treatment, were collected retrospectively. Eleven tumor
samples were collected from primary cancer by means of
transbronchial lung biopsy, one was resected by operation,
and nine were from metastatic sites (four from bone, three
from lymph nodes, one from the brain, and one from the
colon). All specimens underwent histologic examination to
confirm the diagnosis of NSCLC. DNA extraction from
tumor samples was performed using the TaKaRa DEXPAT
kit (TaKaRa Biomedicals, Shiga, Japan).
PCR Amplification
PCR was performed in 25-l volumes using 15 l of
template DNA, 0.75 units of Ampli Taq Gold DNA polymer-
ase (Perkin-Elmer, Roche Molecular Systems, Inc., Branch-
burg, NJ), 2.5 l of PCR buffer, 0.8 mM dNTP, 0.5 M of
each primer, and different concentrations of MgCl2, depend-
ing on the polymorphic marker. A set of designed primers
was used to amplify exon 19 of EGFR (upper primer, 5=-
CAGCCCCCAGCAATATCAGCCTTAGGT-3=; lower
primer, 5=- CACTAGAGCTAGAAAGGGAAAGACATA-
3=). Thirty cycles of amplification were performed using a
thermal cycler (Perkin-Elmer, Foster City, CA) (95°C for 45
seconds, 55.5°C for 30 seconds, 72°C for 30 seconds, fol-
lowed by incubation at 72°C for 10 minutes). The bands were
visualized using a 2100 bioanalyzer, DNA 500 Labchip kit
(Aglient Technologies, Waldbronn, Germany). If no PCR
products were detected by the first PCR, an additional 20
cycles of PCR was carried out and the sample was revisual-
ized. To confirm the deletional mutation in exon 19, and to
detect the mutation in exons 18 and 21 of EGFR, PCR was
performed again using another primer set as described pre-
viously.13
Sequencing
Amplification and sequencing were performed in du-
plicate for each sample using an ABI prism 310 (Applied
Biosystems). The sequences were compared with the Gen-
Bank-archived human sequence for EGFR (accession no.
AY588246).
Trial Design and Statistical Methods
The trial was a two-stage multicenter phase II study.
The primary endpoint was response rate, and secondary
endpoints were disease control rate, safety, TTP, and OS. As
a correlative study, EGFR mutations in tumor and serum
samples were analyzed. The protocol and consent form were
approved by the institutional review board of each participat-
ing hospital. Initially, 15 patients were recruited to the study.
If one of these patients responded to treatment with gefitinib
monotherapy, an additional 10 patients were recruited. If five
or more of these 25 patients responded to therapy, treatment
with gefitinib was concluded to be effective. According to
Simon’s minimax design,21 our study, with a sample size of
25, had an 80% power to support the hypothesis that the true
objective response rate was greater than 30% and a 5%
significance to deny the hypothesis that the true objective
response rate was less than 10%. Assuming a nonevaluability
rate of less than 20%, we projected an accrual of 30 patients.
In analysis of EGFR mutation in serum samples, the categor-
ical variables were compared using the Fisher’s exact test. A
value of p  0.05 was considered significant. The statistical
analyses were performed using the StatView software pack-
age, version 5.0 (SAS Institute, Inc., Cary, NC).
RESULTS
Patients
From October of 2002 to August of 2003, 30 patients
were enrolled into the study. Patient characteristics are sum-
marized in Table 1. The most common histologic subtype
was adenocarcinoma (25 patients [83.3%]). Three patients
had undergone surgery and three had received radiotherapy to
bone or brain metastases. Twenty patients were current or
previous smokers. Twenty-six patients (86.7%) had good PS
(0–1) and 86.7% of enrolled patients had stage IV disease. A
total of 43 sites of metastatic lesions in 26 patients were
diagnosed. Thirteen of the 26 patients had more than one
metastatic lesion. All four patients with stage IIIb disease had
pleural effusion and were ineligible for radiotherapy.
Efficacy
All patients were assessable for tumor response (Table
2). Complete response was not observed. Ten patients
achieved PR, nine had SD as their best response, and 11
patients had progressive disease (PD). The objective response
rate was 33.3% (95% confidence interval, 16.2–49.8%) and
the disease control rate was 63.3% (95% confidence interval,
46.0–80.5%). All responders had adenocarcinoma. Of the
responders, four were male patients and six were female
patients. None of the prognostic factors such as gender (male
versus female), PS (0–1 versus 2), smoking (never-smoker
versus smoker), histology (adenocarcinoma versus nonade-
nocarcinoma), clinical stage (IIIb versus IV), and prior treat-
ment (yes versus no) was significantly associated with tumor
responses (Table 2). Disease control was observed in 19
patients (eight men and 11 women). A significantly higher
disease control rate was observed in female patients (p 
0.018) and nonsmokers (p 0.049). The other factors did not
affect the disease control rate (Table 2).
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TTP and OS
At a median follow-up of 12 months, 20 patients had
died and 26 patients were refractory or had become resistant
to gefitinib monotherapy. Median TTP was 3.3 months
(range, 0.3–19.6 months) and median OS was 10 months
(range, 1.7–21.4 months) (Figure 1. Duration of response for
patients with partial response was 5.8 months. OS and TTP
were not affected by histologic type, smoking, PS, stage, or
prior treatment. However, there was a significant difference
in survival in gender (median survival time, 12 months in
female patients versus 7.7 months in male patients; log-rank
test, p  0.04; Wilcoxon test, p  0.04).
Tolerability
Table 3 shows drug-related adverse events. Twenty-six
patients (86.7%) experienced drug-related adverse events,
most of which were mild. Frequent adverse events included
diarrhea, skin rash, and elevated transaminases. Twenty-two
patients experienced skin toxicities, such as acne, pruritus,
and rash. Grade 3 skin toxicities were observed in two
patients, but these resolved spontaneously during treatment.
Diarrhea was observed in 12 patients (40.0%) and was con-
trolled with antidiarrheal agents such as loperamide. One
patient developed grade 3 diarrhea, which required temporal
interruption of therapy. Two patients developed drug-related
pneumonitis; both were treated with steroid therapy, antibi-
otics, and oxygen inhalation and recovered within a few
weeks. These patients were smokers and had not received
thoracic radiotherapy. No patients experienced hematologic
toxicities.
Postgefitinib Treatment
Twenty-five patients became resistant or were refrac-
tory to gefitinib monotherapy. Eight of these patients received
neither chemotherapy nor radiotherapy because of deteriora-
tion of PS in four patients and withdrawal of informed
consent to chemotherapy in three patients. One patient un-
derwent palliative surgery and two received radiotherapy for
symptomatic brain metastases. Fifteen patients received che-
motherapy as postgefitinib treatment (platinum-based chemo-
therapy in 14 patients and vinorelbine monotherapy in one
patient). Five patients achieved PR and four showed SD by
the second-line chemotherapy.
EGFR Mutations in Tumor Samples
Twenty tumor samples were obtained from 15 patients
retrospectively. Sequencing of exons 18, 19, and 21 in EGFR
was performed in 12 of 20 samples under the same PCR
conditions. EGFR mutations were detected in four tumor
TABLE 1. Patient Characteristics
Characteristic Value
No. of patients 30
Age (yr)
Median 64
Range 44–87
Gender
Male 18
Female 12
Histology
Adenocarcinoma 25
Squamous-cell carcinoma 3
Large-cell carcinoma 2
Stage
IIIB 4
IV 26
Metastatic sites
Pulmonary 16
Bone 12
Brain 11
Others 4
ECOG performance status
0 20
1 6
2 4
Prior treatment
Yes 6
Operation 6
Radiation 3
No 24
Smoking
Yes 20
Pack-years (mean  SD) 51  39
No 10
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Response to Gefitinib Monotherapy and
Prognostic Factors*
No. PR SD PD
RR
(%)
p
Value
DCR
(%)
p
Value
Total 30 10 9 11 33.3 63.3
Prognostic factors
Gender
Male 18 4 4 10 22.2 0.14 44.4 0.018
Female 12 6 5 1 50.0 91.7
Smoking habit
Smoker 20 5 5 10 25 0.231 50 0.049
Nonsmoker 10 5 4 1 50 90
Histologic type
Adenocarcinoma 25 10 8 7 40 0.139 72 0.327
Nonadenocarcinoma 5 0 2 3 0 40
PS
0–1 26 8 8 10 30.8 0.584 61.5 0.999
2 4 2 1 1 50 75
Clinical stage
IIIb 4 2 1 1 50 0.584 75 0.999
IV 26 8 8 19 31 62
Prior treatment
Yes 24 9 5 10 37.5 0.999 58.3 0.215
No 6 1 4 1 16.7 83.3
*RR and DCR were compared between prognostic factors using Fisher’s exact test.
*PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate;
DCR, disease control rate.
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samples (33.3%). Three of them had a 15–base pair deletion
(E746_A750del) in exon 19. Another of them had L858R in
exon 21. The histologic types in patients with EGFR muta-
tions were adenocarcinoma in three and large-cell carcinoma
in one. All patients with E746_A750del in tumor samples had
adenocarcinoma. The responses to gefitinib in these four
patients were PR in two, SD in one, and PD in one. There
were no responders among nine patients without an EGFR
gene mutation.
EGFR Mutations in Serum Samples
The serum DNA in serum samples from 27 NSCLC
patients was examined. Serum DNA was detected in all 54
samples at concentrations of up to 1720 ng/ml.
Exon 19 of EGFR in pretreatment serum samples ob-
tained from 21 of 27 patients (77%) was detected (Figure 2
A). The lower band was also detected in 10 of 27 (37%)
pretreatment serum samples. Sequencing of the PCR products
confirmed that the upper and lower bands corresponded to
wild-type and E746_A750del, respectively (Figure 2 B). No
point mutation in exon 18, 19, or 21 was detected in the PCR
products from serum samples. Wild-type EGFR was detected
in all 10 of the deletion-positive cases. The pattern of bands
was reproducible when using another primer set.13
When compared according to histologic type,
E746_A750del was detected in eight of 25 (32%) cases of
adenocarcinoma, in zero of three cases of squamous carci-
noma, and in two of two cases of large-cell carcinoma (Table
4). In contrast, the serum EGFR status was not correlated
statistically with either the clinical response, the gender, or
the recorded adverse effects (Table 5).
In serum samples obtained after the initiation of ge-
fitinib treatment, 19 of 27 (70%) cases were wild-type–
positive and 14 of 27 (52%) cases were deletion-positive
(Figure 2 C). In the posttreatment serum samples,
E746_A750del was more frequently observed. Furthermore,
the deletional mutant of EGFR was significantly more fre-
quently observed in samples from patients who showed a PR
or SD (12 of 16 cases [75%]) than in samples from patients
with PD (two of 11 cases [18%]) (p  0.0063, Fisher’s exact
test) (Table 6). The deletional mutant EGFR was more
frequently detected in female patients (six of nine cases
[67%]) than in male patients (eight of 18 cases [44%]), but
this difference was not significant (Table 6). No correlations
were seen statistically between the presence of mutation and
the adverse effects.
FIGURE 1. Kaplan-Meier curve showing (A) overall survival
and (B) time to progression in all patients.
TABLE 3. Drug-Related Adverse Events
NCI-CTC Grade No. of Patients %
Diarrhea 1 8 26.7
2 3 10.0
3 1 3.3
Nausea 1 8 26.7
2 2 6.7
3 0 0.0
Vomiting 1 2 6.7
2 0 0.0
3 0 0.0
Skin toxicity 1 15 50.0
2 5 16.7
3 2 6.7
Elevation of transaminases 1 4 13.3
2 1 3.3
3 2 6.7
Pneumonitis 1 0 0.0
2 0 0.0
3 2 6.7
NCI-CTC, National Cancer Institute Common Toxicity Criteria.
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Comparison of EGFR Mutation Status between
Tumor Samples and Serum Samples
Pairs of tumor samples and serum samples were ob-
tained from 12 patients retrospectively (Table 7). The EGFR
mutation status in the tumors was consistent with those in
serum of seven of 12 of the paired samples. Among the other
five patients, EGFR mutation was negative in the tumor and
positive in the serum in four patients, and in the other patient
it was positive in the tumor and negative in the serum, from
whose tumor sample L858R was detected.
DISCUSSION
The overall response of 33.3% in this phase II study
was comparable not only to that achieved in Japanese popu-
lation enrolled in the IDEAL-1 trial (27.5%)7 but also to a
retrospective analysis conducted of patients in Japan.22 Ge-
fitinib monotherapy appeared to be equally effective in pa-
tients with chemotherapy-naive NSCLC and in patients with
pretreated NSCLC.
Drug-related adverse events were generally mild com-
pared with cytotoxic chemotherapy. Grade 3 pulmonary tox-
icities were observed in two patients. In this study, the
FIGURE 2. (A) Detection of
genomic EGFR in the serum of pre-
treatment patients. (B) The se-
quences of the PCR products from
patient 19 (days 0 and 14) are
shown. (C) PCR of the serum sam-
ples obtained on day 14. Serum-
derived genomic DNA PCR was
performed. Exon 19 of EGFR in se-
rum obtained from the patients
was amplified by PCR, and the
products were detected using a
Bioanalyzer. A second round of
PCR (20 cycles) was performed
when no band was detected in the
first round of PCR (30 cycles). Row
numbers indicate the patient num-
ber. *Band detected in the first
round of PCR.
TABLE 4. Frequency of Serum EGFR in Lung Cancer
Patients According to Histology and Response to Gefitinib*
Pre Post
Wild Deletion Wild Deletion
Adenocarcinoma 18/23 8/23 15/22 13/22
Squamous-cell carcinoma 1/2 0/2 3/3 0/3
Large-cell carcinoma 2/2 2/2 1/2 1/2
*A total of 27 samples were obtained from 28 patients both before and after
treatment. A pretreatment sample of patient 2 and a posttreatment sample of patient 17
were lacking.
TABLE 5. Frequency of Serum EGFR in Lung Cancer
Patients According Response to Gefitinib and Gender:
Detection of Deletion-Type Mutation on Day 0*
 – p Value
Response
PR/SD 8 9
PD 2 8 0.2305
Gender
Male 5 12
Female 5 5 0.4153
*A total of 27 samples were obtained from 28 patients both before and after
treatment. A pretreatment sample of patient 2 and a posttreatment sample of patient 17
were lacking. SD, stable disease; PD, progressive disease; PR, partial response; ,
deletion-positive; –, wild-type.
TABLE 6. Frequency of Serum EGFR in Lung Cancer
Patients According to Response to Gefitinib and Gender:
Detection of Deletion-Type Mutation on Day 14*
 – p Value
Response
PR/SD 12 4
PD 2 9 0.0063
Gender
Male 8 10
Female 6 3 0.4197
*A total of 27 samples were obtained from 28 patients both before and after
treatment. A pretreatment sample of patient 2 and a posttreatment sample of patient 17
were lacking. SD, stable disease; PD, progressive disease; PR, partial response; ,
deletion-positive; –, wild-type.
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incidence of drug-related pneumonitis was 6.7% and was
comparable to results of other studies.23,24 Therefore, ge-
fitinib monotherapy as a first-line treatment appears to be
equally tolerable as a second-line treatment.
Thirteen of 22 patients who became resistant or were
refractory to gefitinib monotherapy received salvage chemo-
therapy. The objective response rate was 30.8%, comparable
to that of first-line chemotherapy. These results suggest that
cancer cell populations that are sensitive to gefitinib might
not be identical to those sensitive to chemotherapeutic drugs
such as platinum agents or taxanes.
Somatic mutations in the tyrosine kinase domain of the
EGFR gene were reported, and these mutations induced
increased activity of EGFR and sensitivity to gefitinib in vitro
and the predictive factor of response to gefitinib.13,14 We
evaluated EGFR gene status in 13 tumor samples and de-
tected EGFR gene mutation in four tumors. Objective re-
sponses were achieved in two patients, but one patient
showed PD whose tumor had a 15–base pair deletion muta-
tion in exon 19. This suggested that response to gefitinib may
not be determined by EGFR mutation in exon 19 or 21, and
other mechanisms may relate to gefitinib resistance.
The detection of EGFR mutation from serum samples
was carried out as a correlative study. These results provided
us two major findings: (1) E746_A750del was detectable in
serum sample obtained from NSCLC patients; and (2)
E746_A750del was frequently observed in posttreatment se-
rum samples obtained from the PR and SD patients.
It may be explained that DNA derived from destructive
tumor cells that have responded to gefitinib may be more
frequently observed in the circulating blood. Previous reports
regarding detection of mutations in serum did not elucidate
the changes in mutation status during treatment. We would
like to do this in the next experiments to confirm our specu-
lation. Our hypothesis is that serum detection of EGFR
mutation will be a convenient means of predicting the sensi-
tivity to gefitinib, although we could only demonstrate the
feasibility of the EGFR mutation in serum in this report. We
need to develop a highly sensitive methodology to improve
the predictability of this assay.
In comparison of the mutation status of EGFR in actual
tumors with serum DNA obtained from the same patients
before treatment, 70% of patients who had sequence data
obtained from both serum and tumor samples were conform-
ing. Esteller et al. reported detection of aberrant promoter
hypermethylation of tumor suppressor genes (p16, DAP,
GSTP1, and MGMT) in serum DNA obtained from NSCLC
patients and demonstrated that 73% of serum samples showed
abnormal methylated DNA in the patients with the methyl-
ated primary tumors.19 Another report investigating a point
mutation of the p53 gene and hypermethylation of p16 in
plasma DNA from breast cancer patients demonstrated that
66% of the patients with at least one molecular event in tumor
DNA had some alteration in plasma DNA.25 We believe that
the sensitivity of our assay is equivalently sensitive to those
of these previous reports.
CONCLUSION
In conclusion, 250 mg of oral gefitinib monotherapy as
a first-line treatment produces obvious antitumor activity,
with acceptable toxicities. Oral gefitinib monotherapy as a
first-line treatment merits investigation in further clinical
trials. Using serum samples from NSCLC patients, the EGFR
mutation was detected. The detection of E746_A750del in the
serum of untreated patients was not a predictor of gefitinib
response in this study. However, further prospective studies
using serum samples may be necessary to confirm this con-
TABLE 7. EGFR Mutation Status in Tumor Samples and Serum Samples*
EGFR Mutation Status
Serum Samples
Pre Post
No. Gender Histology Response Tumor Sample Wild Mutation Wild Mutation
43 M Large SD Wild   – 
45 M SCC PD Wild ND ND  –
52 F SCC PD Wild  –  –
53 M Adeno PD Wild – –  –
55 M Adeno PR L858R   – –
57 F Adeno SD Wild – –  
61 M Large PD E746-A750 del    –
64 M Adeno PD Wild  –  –
70 M Adeno PD Wild    –
72 M Adeno SD E746-A750 del  – – 
75 F Adeno PR E746-A750 del    
77 M Adeno PD Wild  –  
*Pairs of both tumor samples and serum samples were obtained from 12 patients. M, male; F, female; SD, stable disease; PD, progressive disease; PR, partial response; SCC,
squamous-cell carcinoma; Adeno, adenocarcinoma; Large, large-cell carcinoma; ND, not determined.
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clusion. The presence of EGFR mutation in serum may be a
useful biomarker for monitoring gefitinib response.
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